WSLHD
Skip navigation
Please use this identifier to cite or link to this item: https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9454
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRussell, M.-
dc.contributor.authorEmmett, L.-
dc.contributor.authorPeric, B.-
dc.contributor.authorSaw, R.-
dc.contributor.authorSpillane, J.-
dc.contributor.authorVazquez, V.-
dc.contributor.authorDuprat, J.-
dc.contributor.authorMoncreiff, M.-
dc.contributor.authorAllan, C.-
dc.contributor.authorLeeuwen, B. V.-
dc.contributor.authorPritchard-Jones, R.-
dc.contributor.authorRastrelli, M.-
dc.contributor.authorde Wilt, H.-
dc.contributor.authorGeh, J.-
dc.contributor.authorHowle, Julie R.-
dc.contributor.authorSpillane, A.-
dc.date.accessioned2024-04-23T04:29:42Z-
dc.date.available2024-04-23T04:29:42Z-
dc.date.issued2024-
dc.identifier.citationEuropean Journal of Surgical Oncology 50(2):107397, 2024-
dc.identifier.urihttps://wslhd.intersearch.com.au/wslhdjspui/handle/1/9454-
dc.description.abstractBACKGROUND: PET/CT is widely used in the staging of patients with melanoma groin lymph node (LN) metastases. This study aims to utilise prospectively collected data to determine the accuracy of this modality in the diagnosis of pelvic metastases in those patients with known inguinal LN involvement. MATERIALS AND METHODS: Data collected as part of the Evaluation of Groin Lymphadenectomy Extent for Metastatic Melanoma (EAGLE-FM) trial was analysed. This was a prospective, randomised, phase III trial. Patients with known inguinal LN metastases were evaluated with 18F-FDG PET/CT. Those without evidence of pelvic LN abnormalities were randomised to inguinal dissection or ilio-inguinal dissection. Those with evidence of abnormality in the pelvic LNs were excluded from the main EAGLE-FM trial but offered ilio-inguinal dissection. Post operative histology results from those patients undergoing ilio-inguinal dissection were analysed to determine the accuracy of PET/CT in the assessment of pelvic LNs RESULTS: There were 101 patients randomised on the EAGLE-FM trial. For this substudy, there were 49 patients who had negative pelvic LNs on PET / CT and 5 patients with positive pelvic nodes on PET / CT included in this analysis. The sensitivity of PET/CT was 25%, specificity 95.6% with positive predictive value (PPV) 50.0% and negative predictive value (NPV) 87.8%. CONCLUSIONS: PET/CT has reasonable NPV but poor PPV. While PET/CT is an important modality in the staging of patients with stage III melanoma, it has limited accuracy in the diagnosis of pelvic LN metastases.-
dc.subjectOncology-
dc.titleAccuracy of PET/CT in the diagnosis of pelvic lymph node metastases in melanoma: A subgroup analysis of the evaluation of groin lymphadenectomy extent for metastatic melanoma (EAGLE-FM) trial-
dc.typeJournal Article-
dc.typeConference Abstract-
dc.identifier.doihttps://dx.doi.org/10.1016/j.ejso.2023.107397-
dc.subject.keywordsinguinal lymph node-
dc.subject.keywordsinguinal region-
dc.subject.keywordslymph node dissection-
dc.subject.keywordslymph node metastasis-
dc.subject.keywordslymphoma-
dc.subject.keywordsmelanoma-
dc.subject.keywordspelvic metastasis-
dc.subject.keywordspelvis lymph node-
dc.subject.keywordspositron emission tomography-computed tomography-
dc.subject.keywordssurgery-
dc.identifier.journaltitleEuropean Journal of Surgical Oncology-
dc.identifier.departmentSurgical Oncology-
dc.contributor.wslhdHowle, Julie R.-
dc.type.studyortrialControlled Study-
dc.type.studyortrialMajor Clinical Study-
dc.type.studyortrialRandomized Controlled Trial-
dc.identifier.affiliationMelanoma Institute Australia, General Surgery, Sydney, Australia-
dc.identifier.affiliationSt Vincent's Hospital, Nuclear Medicine, Sydney, Australia-
dc.identifier.affiliationInstitute of Oncology Ljubljana, Surgical Oncology, Ljubljana, Slovenia-
dc.identifier.affiliationPeter MacCallum Cancer Centre, General Surgery, Melbourne, Australia-
dc.identifier.affiliationHospital de Cancer de Barretos, General Surgery, Barretos, Brazil-
dc.identifier.affiliationAC Camargo, Surgical Oncology, Sao Paulo, Brazil-
dc.identifier.affiliationNorfolk and Norwich University Hospital, Surgery, Norwich, United Kingdom-
dc.identifier.affiliationMater Hospital, General Surgery, Brisbane, Australia-
dc.identifier.affiliationUniversity Medical Center Groningen, Surgical Oncology, Groningen, Netherlands-
dc.identifier.affiliationSt Helens and Knowsley NHS Trust, Surgical Oncology, St Helens, United Kingdom-
dc.identifier.affiliationVeneto Institute of Oncology, Surgical Oncology, Padova, Italy-
dc.identifier.affiliationRadboud University Medical Center, Surgical Oncology, Nijmegen, Netherlands-
dc.identifier.affiliationGuy's and St Thomas' Hospital NHS Trust, Plastic Surgery, London, United Kingdom-
dc.identifier.affiliationWestmead Hospital, Surgical Oncology, Sydney, Australia-
dc.identifier.facilityBlacktown-
dc.identifier.facilityWestmead-
dc.identifier.conferencenameESSO 42 2023. Florence Italy.-
Appears in Collections:Blacktown Mount Druitt Hospital

Files in This Item:
There are no files associated with this item.


Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.